Ubiquitin-conjugating enzyme E2S promotes the progression of lung adenocarcinoma through the NF-κB/GATM signaling axis
4 affiliations
- 1Mongolian Medicine Combines Respiratory and Critical Care Medicine, Affiliated Hospital of Inner Mongolia Minzu University
- 2Institute of Mongolian Medicine Pharmacology, Affiliated Hospital of Inner Mongolia Minzu University
- 3Mongolian and Western Medicine Combined Oncology Department, Affiliated Hospital of Inner Mongolia Minzu University
- 4Medical Laboratory Center, Affiliated Hospital of Inner Mongolia Minzu University
Abstract
Background Ubiquitin-conjugating enzyme E2S (UBE2S) has been implicated in the development of various types of cancer. We previously showed that UBE2S is highly expressed and plays an oncogenic role in lung adenocarcinoma (LUAD). The aim of this study was to elucidate the molecular mechanisms underlying the function of UBE2S in the progression of LUAD. Methods The interaction between UBE2S and its binding proteins was explored using immunoprecipitation coupled with mass spectrometry and coimmunoprecipitation assays. The expression of UBE2S in clinical tissues and LUAD cells was detected by western blotting. The downstream targets of UBE2S identified in our previous microarray study were analyzed and verified using a luciferase assay and chromatin immunoprecipitation–quantitative polymerase chain reaction. In vitro and in vivo functional studies were conducted to confirm the mechanisms involving UBE2S in the progression of LUAD. Results An interaction between UBE2S and IκBα was detected, and UBE2S was negatively correlated with IκBα and positively correlated with p65 in clinical samples of LUAD. Glycine amidinotransferase (GATM) was identified as a downstream gene of UBE2S in LUAD cells. The expression of GATM was negatively regulated by UBE2S and restored by p65 expression. Moreover, we confirmed the binding of p65 to the GATM promoter. GATM was more highly expressed in LUAD tissues than in paracarcinoma tissues. A functional study verified the oncogenic role of UBE2S in the progression of LUAD through GATM/creatine activity. Furthermore, animal experiments confirmed the role of UBE2S in promoting the growth of LUAD tumors through the p65/GATM axis in vivo. Conclusions The newly identified UBE2S/NF-κB/GATM axis may be a target for the treatment of LUAD.
Related
- NEDD4 Promotes Hepatocellular Carcinoma Progression Through Ubiquitin-Dependent Degradation of EPHB6.
- Ubiquitin Chloromethylketone Probe Enables Activity-Based Protein Profiling of E2 Ubiquitin Conjugating Enzymes.
- p38α Signaling Is Associated with Pancreatic Ductal Adenocarcinoma Progression and Represents a Potential Therapeutic Vulnerability
- ACTB promotes ESCC progression by regulating the AKT–mTOR signaling pathway through an m6A-dependent mechanism
- Editorial: E3 ubiquitin ligases: critical roles in cancer progression and therapeutic implications
BibTeX
@article{liu2026ubiquitinconjugating,
title = {{Ubiquitin-conjugating enzyme E2S promotes the progression of lung adenocarcinoma through the NF-κB/GATM signaling axis}},
author = {Zhi Liu and Zhiqiang Han and Dong Wang and Xin Wang and Terigele Qiqige},
journal = {European Journal of Medical Research},
year = {2026},
month = jul,
doi = {10.1186/s40001-026-04928-2},
url = {https://doi.org/10.1186/s40001-026-04928-2},
note = {CC BY},
}
RIS
TY - JOUR
TI - Ubiquitin-conjugating enzyme E2S promotes the progression of lung adenocarcinoma through the NF-κB/GATM signaling axis
AU - Zhi Liu
AU - Zhiqiang Han
AU - Dong Wang
AU - Xin Wang
AU - Terigele Qiqige
PY - 2026
DA - 2026/07/01
JO - European Journal of Medical Research
DO - 10.1186/s40001-026-04928-2
UR - https://doi.org/10.1186/s40001-026-04928-2
AB - Background Ubiquitin-conjugating enzyme E2S (UBE2S) has been implicated in the development of various types of cancer. We previously showed that UBE2S is highly expressed and plays an oncogenic role in lung adenocarcinoma (LUAD). The aim of this study was to elucidate the molecular mechanisms underlying the function of UBE2S in the progression of LUAD. Methods The interaction between UBE2S and its binding proteins was explored using immunoprecipitation coupled with mass spectrometry and coimmunoprecipitation assays. The expression of UBE2S in clinical tissues and LUAD cells was detected by western blotting. The downstream targets of UBE2S identified in our previous microarray study were analyzed and verified using a luciferase assay and chromatin immunoprecipitation–quantitative polymerase chain reaction. In vitro and in vivo functional studies were conducted to confirm the mechanisms involving UBE2S in the progression of LUAD. Results An interaction between UBE2S and IκBα was detected, and UBE2S was negatively correlated with IκBα and positively correlated with p65 in clinical samples of LUAD. Glycine amidinotransferase (GATM) was identified as a downstream gene of UBE2S in LUAD cells. The expression of GATM was negatively regulated by UBE2S and restored by p65 expression. Moreover, we confirmed the binding of p65 to the GATM promoter. GATM was more highly expressed in LUAD tissues than in paracarcinoma tissues. A functional study verified the oncogenic role of UBE2S in the progression of LUAD through GATM/creatine activity. Furthermore, animal experiments confirmed the role of UBE2S in promoting the growth of LUAD tumors through the p65/GATM axis in vivo. Conclusions The newly identified UBE2S/NF-κB/GATM axis may be a target for the treatment of LUAD.
SN - 2047-783X
ER -